Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

Ajinomoto CELLiST Korea launches CELLiSTTM AAV production supplement 1 to improve gene therapy manufacturing efficiency

By Drug Discovery Editor | December 12, 2025

Ajinomoto, founded in 1909 after chemist Kikunae Ikeda isolated glutamate from kelp broth and commercialized it as MSG, has evolved from seasoning to cell culture media over more than a century

Now, its Korean subsidiary Ajinomoto CELLiST Korea, which focuses on cell culture media development and manufacturing, announced the launch of CELLiSTTM AAV Production Supplement 1, a new medium supplement designed to improve viral vector productivity in gene therapy manufacturing.

The supplement was developed through a collaboration between Ajinomoto Co., Inc. of Tokyo and its U.S.-based consolidated subsidiary Forge Biologics, a contract development and manufacturing organization specializing in adeno-associated virus production. Demonstration studies showed that CELLiSTTM AAV Production Supplement 1 increased viral vector productivity by approximately 1.3 to 2 times compared with conventional culture methods. Results from the joint research were presented at the Japan Society of Gene and Cell Therapy meeting in July 2025.

Improving viral vector productivity remains one of the major challenges facing the gene therapy sector, particularly as developers seek to reduce manufacturing costs while scaling production. The global gene therapy market is projected to grow from about USD 7 billion in 2022 to USD 46 billion by 2030, increasing demand for more efficient production technologies for both common and rare disease therapies.

Ajinomoto CELLiST Korea has spent more than 30 years developing cell culture media for biopharmaceutical manufacturing, with a portfolio of CELLiSTTM products optimized for CHO and HEK293 cell lines. By combining the Ajinomoto Group’s formulation optimization technologies with Forge Biologics’ experience in large-scale AAV manufacturing, the companies aimed to address key production bottlenecks in gene therapy manufacturing. Ajinomoto CELLiST Korea plans to support customers primarily in Asia that are seeking to improve viral vector production efficiency.

“We are pleased to introduce CELLiSTTM AAV Production Supplement 1 to our customers,” said Sugiyama, president of Ajinomoto CELLiST Korea. “By building on the Ajinomoto Group’s research capabilities, we aim to help gene therapy developers improve productivity, scalability, and manufacturing consistency.”

Ajinomoto CELLiST Korea continues to expand its AminoScience-based solutions for biopharmaceutical manufacturing, supporting applications ranging from monoclonal antibodies to next-generation cell and gene therapies.


Filed Under: Uncategorized
Tagged With: AAV, Adeno-associated virus, Ajinomoto, biopharmaceutical manufacturing, cell and gene therapy, cell culture media, Forge Biologics, gene therapy, gene therapy manufacturing, viral vectors
 

Related Articles Read More >

Novo Nordisk announces strategic partnership with AWS. Will it be enough to turn around its financial performance?
Boehringer Ingelheim eyes MASH as the next front for survodutide, a GLP-1/glucagon receptor dual agonist
Ozempic
Canada approves generic semaglutide from Dr. Reddy’s, a G7 first enabled by Novo Nordisk’s lapsed CAD$250 patent
From list price to net price: How finance leaders decode real drug costs
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE